Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors.
作者： Peter H Jones , Harold Bays
DOI:
关键词:
摘要: Colesevelam HCl is a bile acid sequestrant (BAS) which has been specifically designed with unique structure for the purpose of improving tolerability and reducing potential drug interactions compared to older BAS, such as cholestyramine colestipol. As class, BAS are known reduce cholesterol glucose levels, atherosclerotic coronary heart disease (CHD) risk monotherapy, in combination other lipid-altering therapies. shown total low-density lipoprotein (LDL) approved cholesterol-lowering since year 2000. It also levels. This discussion reviews mechanisms by lower cholesterol, levels patients type 2 diabetes mellitus. Finally this paper colesevelam HCl’s pharmacology, lipid efficacy, safety/tolerability, clinical use.
参考文章(45)
Jones Peter H., Rationale for intensive statin treatment in high-risk patients. Preventive Cardiology. ,vol. 9, pp. 91- 95 ,(2006) , 10.1111/J.1520-037X.2000.4565.X
Carole Brendel, Kristina Schoonjans, Oronza A. Botrugno, Eckardt Treuter, Johan Auwerx, The Small Heterodimer Partner Interacts with the Liver X Receptor α and Represses Its Transcriptional Activity Molecular Endocrinology. ,vol. 16, pp. 2065- 2076 ,(2002) , 10.1210/ME.2001-0194
Michael H. Davidson, Kevin C. Maki, Thomas A. Pearson, Richard C. Pasternak, Prakash C. Deedwania, James M. McKenney, Gregg C. Fonarow, David J. Maron, Benjamin J. Ansell, Luther T. Clark, Christie M. Ballantyne, Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. American Journal of Cardiology. ,vol. 96, pp. 556- 563 ,(2005) , 10.1016/J.AMJCARD.2005.04.019
Shinya Shibata, Kazuhito Hayakawa, Yukari Egashira, Hiroo Sanada, Roles of nuclear receptors in the up-regulation of hepatic cholesterol 7α-hydroxylase by cholestyramine in rats Life Sciences. ,vol. 80, pp. 546- 553 ,(2007) , 10.1016/J.LFS.2006.10.003
Alan F. Hofmann, The Continuing Importance of Bile Acids in Liver and Intestinal Disease JAMA Internal Medicine. ,vol. 159, pp. 2647- 2658 ,(1999) , 10.1001/ARCHINTE.159.22.2647
Harold Bays, Christie Ballantyne, Adiposopathy: why do adiposity and obesity cause metabolic disease? Future Lipidology. ,vol. 1, pp. 389- 420 ,(2006) , 10.2217/17460875.1.4.389
Harold Bays, Evan A Stein, Pharmacotherapy for dyslipidaemia – current therapies and future agents Expert Opinion on Pharmacotherapy. ,vol. 4, pp. 1901- 1938 ,(2003) , 10.1517/14656566.4.11.1901
T. LUNDÅSEN, C. GÄLMAN, B ANGELIN, M. RUDLING, Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. Journal of Internal Medicine. ,vol. 260, pp. 530- 536 ,(2006) , 10.1111/J.1365-2796.2006.01731.X
Harold E. Bays, Michael Davidson, Michael R. Jones, Stacey L. Abby, Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. American Journal of Cardiology. ,vol. 97, pp. 1198- 1205 ,(2006) , 10.1016/J.AMJCARD.2005.11.039
Harold Bays, Statin Safety: An Overview and Assessment of the Data—2005 American Journal of Cardiology. ,vol. 97, ,(2006) , 10.1016/J.AMJCARD.2005.12.006